Skip to content
Clinical Trials – home

GLIMEPIRIDE: A Comprehensive Guide for Patients

1 / 2
trials open to patients / all trials
2+
Countries

In short

This article examines the use of Glimepiride, a medication for type 2 diabetes, in various clinical trials. Glimepiride belongs to the sulfonylurea class of drugs and is often used alone or in combination with other diabetes medications. The trials discussed here investigate Glimepiride's effectiveness, safety profile, and interactions with other drugs in treating diabetes and related conditions.

At a glance

Primary Use
Treatment of type 2 diabetes
Drug Class
Sulfonylurea
Common Dosages
1-4 mg daily
Combination Treatments
Often combined with Metformin (e.g., Amaryl M)
Key Clinical Trials
Bioequivalence studies, comparison with Sitagliptin, cardiovascular safety in heart failure patients
Primary Outcomes Measured
HbA1c levels, fasting plasma glucose, pharmacokinetic parameters
Safety Considerations
Hypoglycemia risk, cardiovascular effects
Special Populations Studied
Patients with type 2 diabetes and chronic heart failure

What is Glimepiride?

Glimepiride is a medication used to treat type 2 diabetes mellitus. It belongs to a class of drugs called sulfonylureas, which help lower blood sugar levels in people with diabetes. Glimepiride is also known by its brand name Amaryl. This medication is typically prescribed when diet, exercise, and weight reduction alone are not sufficient to control blood sugar levels in patients with type 2 diabetes.

How Glimepiride Works

Glimepiride works by stimulating the pancreas to produce more insulin, which is a hormone that helps regulate blood sugar levels. By increasing insulin production, glimepiride helps lower blood glucose (sugar) levels in patients with type 2 diabetes. This medication is particularly effective in improving both fasting blood glucose (blood sugar levels when you haven't eaten) and postprandial glucose (blood sugar levels after meals).

Conditions Treated by Glimepiride

The primary condition treated by glimepiride is Type 2 Diabetes Mellitus. This is a chronic condition characterized by high blood sugar levels due to the body's inability to properly use insulin or produce enough of it. Glimepiride is typically prescribed for patients whose blood sugar levels cannot be adequately controlled through diet and exercise alone.

Dosage and Administration

Glimepiride is available in tablet form and is typically taken orally. The dosage can vary depending on the individual patient's needs and response to treatment. Some common dosages include:

  • Starting dose: Often 1 mg or 2 mg once daily, taken with breakfast or the first main meal of the day.
  • Dose adjustments: The dose may be increased gradually, usually every 1-2 weeks, based on the patient's blood glucose levels and tolerance. The maximum daily dose is typically 4 mg.
  • In some cases, doses up to 6 mg daily may be prescribed, but this is less common.

It's important to take glimepiride exactly as prescribed by your healthcare provider. Never adjust your dose without consulting your doctor first.

Combination Therapies

Glimepiride is often used in combination with other diabetes medications to achieve better blood sugar control. Some common combinations include:

  • Glimepiride + Metformin: This combination, sometimes referred to as Amaryl M, is frequently used when either drug alone doesn't provide adequate blood sugar control. It combines the insulin-stimulating effects of glimepiride with the insulin-sensitizing effects of metformin.
  • Glimepiride vs. Sitagliptin: Some studies have compared the effectiveness of glimepiride to other diabetes medications like sitagliptin. These comparisons help determine which medication might be more suitable for different patient groups.

Efficacy and Benefits

Clinical trials have shown several benefits of glimepiride treatment:

  • HbA1c Reduction: Glimepiride has been shown to effectively reduce HbA1c levels. HbA1c is a measure of average blood sugar levels over the past 2-3 months.
  • Fasting Plasma Glucose (FPG) Improvement: Studies have demonstrated that glimepiride can significantly lower fasting blood sugar levels.
  • Postprandial Glucose Control: Glimepiride also helps in managing blood sugar levels after meals.
  • Combination Therapy Benefits: When used in combination with metformin, glimepiride has shown superior results in glycemic control compared to either medication used alone.

Side Effects and Safety

While glimepiride is generally well-tolerated, it can cause some side effects. The most common and important side effect to be aware of is:

  • Hypoglycemia: This is when blood sugar levels drop too low. Symptoms can include shakiness, dizziness, sweating, and confusion. To minimize this risk, patients are often given glucose solutions during clinical trials.

Other potential side effects may include weight gain, gastrointestinal disturbances, and allergic reactions. It's important to discuss any side effects with your healthcare provider.

Monitoring and Follow-up

Regular monitoring is crucial when taking glimepiride. This typically includes:

  • Blood Glucose Monitoring: Regular checks of both fasting and postprandial (after-meal) blood sugar levels.
  • HbA1c Tests: Periodic checks of HbA1c levels to assess long-term blood sugar control.
  • Liver and Kidney Function Tests: To ensure the medication is being properly processed by your body.
  • Weight Monitoring: As weight changes can affect diabetes management.

Your healthcare provider will determine the appropriate monitoring schedule based on your individual needs and response to treatment.

Questions people often ask

Conditions where Glimepiride is being studied

Each condition opens its own overview and trial list

Trials with Glimepiride

Recruiting trials first

See all 2 →
Quick filters
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).